{"prompt": "['Analyses will include summaries of the following safety endpoints:', 'Incidence, nature and severity of all AEs, Grade 3 AEs, SAEs and cardiac AEs', '(including LVEF events). Cardiac AE analyses will focus on the incidence of patients with', 'heart failure (NYHA, NCI-CTCAE [heart failure] Grades 2, 3, 4, and 5). Left ventricular', 'ejection fraction data summaries will include the incidence of patients with LVEF', 'decreases with an absolute decrease of at least 10 percentage points from baseline and', 'to below 50%.', 'Incidence of premature withdrawal from study treatment', 'Targeted vital signs and physical findings', 'Targeted clinical laboratory test results', 'The analysis of AEs will focus on treatment-emergent AEs, i.e. AEs occurring on or after the', 'day of first study drug administration. Non-treatment emergent AEs (i.e. those occurring', 'before start of study treatment) will be listed (with a flag to identify those AEs that continued', 'into on-study treatment cycles). Adverse events will be coded using MedDRA. All AEs and', 'laboratory abnormalities will be graded according to NCI CTCAE version 4.0.', 'The incidence of all AEs, AEs leading to premature discontinuation or interruption of study', 'treatment, SAEs, AEs of grade 3 and cardiac AEs will be summarized according to the', 'primary system-organ class and by preferred term. The incidence of deaths and cause of', 'deaths will be listed and summarized by treatment arm and overall.', 'Adverse events will be summarised by treatment arm for the Treatment Cross-over Period,', 'Treatment Continuation Period and overall.', 'Vital signs and targeted physical examination variables will be summarized by treatment arm', 'over time.', 'Clinical laboratory parameters will be presented in shift tables of NCI CTCAE grade at', 'baseline against worst grade recorded during each treatment period and overall. Laboratory', 'parameters will be summarized by absolute value and change from baseline.', 'Concomitant medication will be coded and tabulated in summary tables.', 'Exposure to study treatment, including the number of cycles administered, duration of', 'treatment (calculated from date of first treatment date to the last treatment date) and dosing', 'information (e.g. dose interruptions, modifications and delays) will be summarized for each', 'treatment arm.', 'To evaluate the safety of switching from pertuzumab and trastuzumab FDC SC to P+H IV', 'and from P+H IV to pertuzumab and trastuzumab FDC SC, AE summaries will also by', 'produced for the Treatment Cross-over Period by treatment arm and actual treatment. An', 'AE will be allocated to the treatment received on or before the AE start date.', 'Adverse events that started during the first three cycles of the Treatment Cross-over Period', 'and continued into subsequent cycles (even if the AE changed severity grade) will be', 'summarized by the route of administration during which it first occurred. These AEs will be', 'flagged in listings.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '83 / Protocol MO40628, Version 12']['6.5.2', 'Efficacy Analyses', 'Secondary efficacy endpoints include IDFS, IDFS including second primary non-breast', 'cancer, DDFS and OS.', 'IDFS is defined as the time from randomization to the first occurrence of one of the following', 'events:', 'Ipsilateral invasive breast tumour recurrence (i.e., an invasive breast cancer involving the', 'same breast parenchyma as the original primary lesion),', 'Ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast', 'cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the lipsilateral', 'breast),', 'Distant recurrence (i.e., evidence of breast cancer in any anatomic site other than the', 'two above mentioned sites that has either been histologically confirmed or clinically', 'diagnosed as recurrent invasive breast cancer),', 'Contralateral invasive breast cancer,', 'Death attributable to any cause, including breast cancer, non-breast cancer, or unknown', 'cause (but cause of death should be specified, if possible).', 'Note: Ipsilateral or contralateral in situ disease and second primary non-breast cancers', '(including in situ carcinomas and non-melanoma skin cancers) will not be counted as', 'recurrence.', 'IDFS including second primary non-breast cancer is defined as IDFS with second primary', 'non-breast invasive cancer (with the exception of non-melanoma skin cancers and in situ', 'carcinoma of any site) included as an event.', 'DDFS is defined as the time from randomization to the date of distant breast cancer', 'recurrence.', 'OS is defined as the time from randomization to death from any cause.', 'The time-to-event endpoints IDFS, IDFS including second primary non-breast cancer, DDFS', 'and OS will be summarized by treatment arm using the Kaplan Meier approach. The median', 'and the corresponding 95% CI will be reported. Patients who have experienced none of', 'these events at the time of analysis (clinical-cut off) and patients who are lost to follow up will', 'be censored at their last clinical assessment date. A frequency table will also be provided for', 'type of IDFS event.', 'Descriptive analyses will be provided for sub-groups of interest, including neoadjuvant', 'chemotherapy regimen (anthracyclines + taxanes / carboplatin + taxanes / taxanes only),', 'neoadjuvant treatment response (pCR / non-pCR), and hormone receptor status (positive /', 'negative).', '6.6', 'OPTIONAL-INTERIN ANALYSES', 'An interim safety analysis may be conducted. The decision to perform an interim safety', 'analysis will be based on ongoing review of safety data by the Medical Monitor. If conducted,', \"the results of this interim analysis will be evaluated by a Sponsor's Internal Data Monitoring\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '84 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}